Testing for COVID-19: A Personal Reflection
In November of 2019, I was working for one of our clients in WuXi City, Jiangsu province when the global pandemic that became COVID-19 caught fire in Wuhan, China. Having…
0 Comments
March 13, 2020
Chamow & Associates Website Redesign
Chamow & Associates is pleased to announce the launch of our new website. Our updated site was created with our valued clients, and future clients, in mind. We have introduced…
March 5, 2020
mAb Product Stability Can Be Predicted from Cellular Signs of Stress
In designing cell culture processes for the manufacture of biologics, we often place the greatest focus on product titer. Titer is determined by multiplying together two factors: the amount of…
February 3, 2020
What to Look for in a CDMO
Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a…
January 16, 2020
The State of Monoclonal Antibodies in Medicine Today
Once again, the journal mAbs has published its 11th annual “Antibodies to Watch” article as an overview of exciting antibody products staged for significant advances in the coming year, authored…
January 3, 2020
Determining Priorities When Looking for a CDMO
Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a…
December 20, 2019
Bay Area Biotechnology Is Growing into the Mid-Peninsula
South San Francisco is home to the largest biotech cluster in the world, with over 200 biotech companies, and 11.5-million square feet of biotech space on 500 acres. But 16…
December 3, 2019
Reasons to Use a CDMO
Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a potential…
November 13, 2019
Prestigious Medical Research Award Goes to Herceptin
Monoclonal antibodies (mAbs) as a therapeutic modality were developed over an 11-year period, from the first production of mAbs in 1975 to the first licensing of mAb therapeutic Orthoclone OKT3…
October 8, 2019
Ebola infection is curable—A phenomenal breakthrough
After the 2014 Ebola outbreak in West Africa, researchers wanted to test ZMapp, a new, experimental drug that had been used during that outbreak on some infected patients, along with…
September 19, 2019